Skip to main content

Rhodri Allen

Rhodri Allen

Quality Manager

Rhodri Allen

Rhodri Allen

Quality Manager

Rochelle Ahmed

Rochelle Ahmed

Senior Research and Development Scientist

Rochelle Ahmed

Rochelle Ahmed

Senior Research and Development Scientist

Gonzague Brochard

Gonzague Brochard

Production Technician

Gonzague Brochard

Gonzague Brochard

Production Technician

Sandy Burns

Sandy Burns

Financial Controller

Sandy Burns

Sandy Burns

Financial Controller

Thomas Paul Descamps

Thomas-Paul Descamps

Chief Executive Officer

» Read Bio

Thomas Paul Descamps

Thomas-Paul Descamps

Chief Executive Officer

TP Holds a Masters Degree in General Management from the University Paris IX Dauphine and a Diploma of Finance and Marketing from Sciences-Po Paris.

Since 1993 he has held many positions in Sales and Marketing with global pharmaceutical players such as GSK and Eli Lilly.

In 2004, he joined Actelion -a rare disease fast growing Pharmaceutical company- where as Director Commercial Operations he successfully set up the commercial team of the French affiliate, achieving best worldwide sales per Million Inhabitants.

In 2008 he broadened his expertise in Joining Ipsen as a VP in charge of the Neurology Global portfolio management, including Franchise strategy, Product Clinical Development, Business Development etc.

In 2011 he successfully expanded an Ipsen US acquisition Start-Up in Europe, achieving 6 countries opening in 6 months.

In 2013 he took up an offer to move to London to join Allergan in a European Commercial role before moving in 2015 to a French mid-size pharma company as VP Europe.

Since 2014 TP has also acted as a Business angel. He helped raise >£4M for Jellagen during the two last rounds and is an investor and Chairman of the board at Histide, a Swiss Biotech Start-Up.

In April 2016, Thomas-Paul [TP] was appointed as a Senior Adviser to the CEO of Jellagen, and Board Observer. In April 2018 he has been appointed as CEO, Executive Director and Member of Jellagen’s Board.

David Matthews

David Matthews

Production Technician

David Matthews

David Matthews

Production Technician

Anthony Morris

Tony Morris

Production Manager

Anthony Morris

Tony Morris

Production Manager

Mojdeh Oreyzi

Mojdeh Oreyzi

Senior Executive Assistant / Company Secretary

Mojdeh Oreyzi

Mojdeh Oreyzi

Senior Executive Assistant / Company Secretary

Ethan Phillips

Ethan Phillips

Research Technician

Ethan Phillips

Ethan Phillips

Research Technician

Victoria Phyfer

Victoria Phyfer

Research Technician

Victoria Phyfer

Victoria Phyfer

Research Technician

Alex Picton

Alex Picton

Head of Operations

Alex Picton

Alex Picton

Head of Operations

Taylor Raines

Taylor Raines

Analytical Validation Scientist

Taylor Raines

Taylor Raines

Analytical Validation Scientist

Stephanie Scaife

Stephanie Scaife

Lab Technician

Stephanie Scaife

Stephanie Scaife

Lab Technician

Oliver Schofield

Oliver Schofield

Chief Financial Officer

Oliver Schofield

Oliver Schofield

Chief Financial Officer

Derek Silcock

Derek Silcock

Head of Production Development

Derek Silcock

Derek Silcock

Head of Production Development

Andrew Mearns Spragg

Professor Andrew Mearns Spragg

Founder, CSO & Managing Director

» Read Bio

Andrew Mearns Spragg

Professor Andrew Mearns Spragg

Founder, CSO & Managing Director

Andrew holds a first-class BSc degree in Microbiology and PhD in Marine Biotechnology from Heriot-Watt University, Edinburgh. Andrew was awarded a Royal Society of Edinburgh Enterprise Fellowship at St. Andrews University in 2000 to support the creation of his first marine biotechnology enterprise.

For the past 18 years, his career has focused on the creation of companies involved with the commercial exploitation of marine biotechnologies. Andrew has successfully raised to date over £16M in equity finance from VCs and Angels and has secured competitive grant funding from EU and UK sources worth >£3M. He was the recipient of the 2007 Gannochy Award and Medal from the Royal Society of Edinburgh, Scotland’s highest award for Innovation and his entrepreneurial achievements were recognised through winning the Ernst & Young Entrepreneur of the year 2008 in Health Care for Scotland. Andrew was elected a member of the Royal Society of Edinburgh’s Young Academy from 2011 – 2015 and holds Honorary Professorships from the University of Stirling (2012-2016) and University of the Highlands and Islands. He is a Fellow of the Royal Society of Chemistry and the Royal Society of Biology.

Andrew founded Jellagen in 2013, where he raised more than £6.5M, established in-house collagen standards and first data set. He also built the first manufacturing plant of Jellyfish Collagen. At the occasion of the second funding round, he decided to step down from his CEO role to fully dedicate his time, knowledge and energy to the scientific potential of the company. Andrew is now member of the Executive Committee, responsible for Scientific and Technology strategy, Product Development and Business Development activities.

Collagen Type 0 Whitepaper

Find out how Collagen Type 0 can revolutionise Regenerative Medicine

In this whitepaper we explore:

  • Where Collagen Type 0 comes from
  • Properties of Collagen Type 0
  • Biocompatibility and anti-inflammatory properties of Collagen Type 0
  • In Vivo wound case study
  • Clinical Applications for Collagen Type 0

Download Whitepaper